Alcohol Dependence Clinical Trial
Official title:
Stress, HPA Dysfunction, and Relapse in Alcoholism
This proposal is part of the INIA Stress Consortium. This study will
1. explore the contributions of lifetime trauma, recent stress, and alcohol use on
stress-hormone axis disruption in treatment seeking, one-month abstinent,
alcohol-dependent subjects
2. assess the combined contributions of stress-hormone axis disruption and episodic stress
on the risk of prospective drinking following treatment
3. determine the role of neurosteroids in alcohol use.
The hypothalamic-pituitary-adrenal (HPA) system is suggested as a key biologic link in
stress-induced relapse. The HPA axis provides a regulatory feedback network between the
brain and the body's behavioral and physiologic responses to stress, recovery, and
adaptation. Both trauma and chronic alcohol use produce persistent disturbances in the HPA
response to stress. The chronic use of alcohol may also impair the stress-induced release of
neurosteroids, compounds that directly modulate central nervous system activity. Thus,
altered cortisol and neurosteroid responsiveness during abstinence may impair the central
nervous system's ability to mount an appropriate response to environmental stressors,
heightening the probability of relapse. However, the relationship between stress, relapse,
and HPA axis disturbances remains tentative. In the proposed study, the investigators will
assess the contribution of trauma, stress, and alcohol use upon pituitary-adrenocortical
functioning in alcohol dependence. The relative contribution of adrenocortical disruption
and episodic stress to prospective drinking behaviors will then be determined.
Hypothesis: We hypothesize (1) that lifetime trauma, recent stress, and chronic alcohol use
will additively contribute to HPA axis disruption, (2) alterations in glucocorticoid and
neurosteroid release as well as episodic stress will predict a return to drinking.
Methods: One hundred treatment-seeking, one-month abstinent, alcohol-dependent subjects will
be studied. Standardized assessments will be used to assess childhood and adult trauma as
well as recent (six months) stress. Pituitary-adrenal (including ACTH (adrenocorticotropin),
cortisol, and neurosteroids) responses to both neuroendocrine [ovine corticotropin releasing
hormone (oCRH), cosyntropin, and dexamethasone] and experiential (public speaking)
challenges will be measured. Drinking behavior and episodic stress will be prospectively
assessed for six months following neuroendocrine assessment.
Significance: If our hypotheses are supported, a definitive connection between previous
trauma, biological stress response mechanisms, and ongoing stress upon prospective drinking
behavior will be demonstrated. The identification of a specific biologic mechanism that
underlies this association will provide a fertile framework for the development of targeted
pharmacological interventions to decrease relapse in this vulnerable population. In
addition, elucidating the concurrent contributions of stress-response biologic systems and
externals stressors will provide the therapist and patient with a constellation of specific
risk factors for focused treatment.
;
Observational Model: Case-Only, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02901041 -
Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism
|
Phase 3 | |
Completed |
NCT03340051 -
Remote Alcohol Monitoring and Episodic Thinking
|
N/A | |
Not yet recruiting |
NCT06444243 -
Psilocybin-assisted Therapy for Alcohol Use Disorder
|
Phase 2 | |
Completed |
NCT02486900 -
Neurofeedback & Alcohol Dependence
|
N/A | |
Completed |
NCT02705898 -
Lifestyle Physical Activity Intervention for Depressed Alcohol Dependent Women
|
N/A | |
Completed |
NCT02179749 -
Mifepristone Treatment of Alcohol Use Disorder
|
Phase 2 | |
Completed |
NCT02197598 -
Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use
|
Phase 4 | |
Recruiting |
NCT02385643 -
The Efficacy of A Smartphone-based Support System to Reinforce Alcohol Abstinence in Treatment-seeking Patients
|
N/A | |
Completed |
NCT01828866 -
Eye Movement Desensitization and Reprocessing (EMDR) in Alcohol Dependent Patients
|
N/A | |
Terminated |
NCT01408641 -
Topiramate for Alcohol Use in Posttraumatic Stress Disorder
|
N/A | |
Active, not recruiting |
NCT01182766 -
New Treatment for Alcohol and Nicotine Dependence
|
Phase 2/Phase 3 | |
Completed |
NCT01342549 -
Treatment Strategy for Alcohol Use Disorders in Veterans With TBI
|
Phase 3 | |
Completed |
NCT02193204 -
Chronic Alcohol, Stress Inflammatory Response and Relapse Risk
|
N/A | |
Completed |
NCT01165541 -
A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency
|
Phase 2 | |
Completed |
NCT01176591 -
HBPL Study of the Impact of the NK1 Antagonist Aprepitant
|
Phase 2 | |
Completed |
NCT00585780 -
Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse
|
Phase 1/Phase 2 | |
Completed |
NCT01056484 -
Mindfulness Meditation for Health
|
Phase 2 | |
Completed |
NCT00607620 -
Disseminating Organizational SBI Services at Trauma Centers
|
N/A | |
Completed |
NCT00884884 -
Aripiprazole and Topiramate on Free-Choice Alcohol Use
|
Phase 2/Phase 3 | |
Completed |
NCT00463346 -
Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism
|
Phase 3 |